Annals of hepatology最新文献

{"title":"A putative hepatitis B virus sequence motif associated with hepatocellular carcinoma in South African adults","authors":"Tongai G. Maponga ,&nbsp;Anna L. McNaughton ,&nbsp;Cori Campbell ,&nbsp;Mariateresa de Cesare ,&nbsp;Jolynne Mokaya ,&nbsp;Sheila F. Lumley ,&nbsp;David Bonsall ,&nbsp;Camilla LC Ip ,&nbsp;Haiting Chai ,&nbsp;Christo Van Rensburg ,&nbsp;Richard H. Glashoff ,&nbsp;Elizabeth Waddilove ,&nbsp;Wolfgang Preiser ,&nbsp;Jason T. Blackard ,&nbsp;M. Azim Ansari ,&nbsp;Anna Kramvis ,&nbsp;Monique I. Andersson ,&nbsp;Philippa C Matthews","doi":"10.1016/j.aohep.2024.101763","DOIUrl":"10.1016/j.aohep.2024.101763","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Chronic hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). In African populations, HCC frequently presents at an advanced stage with poor outcomes. We applied whole genome sequencing (WGS) to compare HBV genomes in individuals with and without HCC.</div></div><div><h3>Materials and Methods</h3><div>We identified adults with HBV infection, with and without complicating HCC, in Cape Town, South Africa. We generated HBV WGS using pan-genotypic probe-based enrichment followed by Illumina sequencing.</div></div><div><h3>Results</h3><div>Compared to the non-HCC group, HCC patients were more likely to be male (<em>p</em> &lt; 0.0001), older (<em>p</em> = 0.01), HIV-negative (<em>p</em> = 0.006), and have higher HBV viral loads (<em>p</em> &lt; 0.0001). Among 19 HCC and 12 non-HCC patients for whom WGS was obtained, genotype A dominated (74 %), of which 96 % were subgenotype A1. PreS2 deletions (Δ38–55) were enriched in HBV sequences from HCC patients (<em>n</em> = 7). The sequence motif most strongly associated with HCC comprised either a deletion or polymorphism at site T53 in PreS2 – collectively coined ‘non-T53’ – together with a basal core promoter (BCP) mutation G1764A (AUROC = 0.79).</div></div><div><h3>Conclusions</h3><div>In this setting, HBV sequence polymorphisms and deletions are associated with HCC, and ‘non-T53 + G1764A’ represents a putative signature motif for HCC. Additional investigations are needed to disaggregate the impact of other demographic, clinical, and environmental influences, to ascertain the extent to which viral polymorphisms contribute to oncogenesis, and to determine whether HBV sequence is a useful biomarker for HCC risk stratification.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101763"},"PeriodicalIF":3.7,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of HAPA theory-based case management in patients with metabolic dysfunction-associated steatotic liver disease","authors":"Jia Mei,&nbsp;Yuncai Xie,&nbsp;Pingping Huang,&nbsp;Yudi Jin,&nbsp;Xia Wang,&nbsp;Ying Chen","doi":"10.1016/j.aohep.2025.101790","DOIUrl":"10.1016/j.aohep.2025.101790","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease affecting people's health, with its incidence increasing year by year. This study aims to determine the effects of Health Action Process Approach (HAPA)-based health management on patients diagnosed with MASLD.</div></div><div><h3>Patients and Methods</h3><div>204 MASLD patients were selected from the hospital's physical examination center from January 1, 2023, through April 1, 2023. Patients are randomly assigned to two groups (<em>n</em> = 102 each) using an envelope-based. Individuals in the experimental group received case management based on the HAPA theory, while standard health management was employed for control group patients. All subjects were monitored over a 6-month period, comparing body mass index (BMI), waist-to-hip ratio (WHR), levels of liver function (AST, ALT), blood lipid levels (total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and health behaviours (as assessed with the HPLP-II health promotion lifestyle scale) before and after the intervention.</div></div><div><h3>Results</h3><div>Post-intervention, the experimental group showed significant improvement in fatty liver (<em>P</em> &lt; 0.01) and reductions in biochemical indices, BMI, and WHR levels (<em>P</em> &lt; 0.05), and a corresponding improvement in HDL-C levels (<em>P</em> &lt; 0.001), compared to the control group. Additionally, patients in the experimental group exhibited significantly better health behaviour scores related to stress management, exercise, diet, and health responsibility compared to controls (<em>P</em> &lt; 0.01).</div></div><div><h3>Conclusions</h3><div>HAPA theory-based case management can improve blood lipid profiles, liver function, and health-related behaviours in MASLD patients, highlighting its potential as an effective management strategy for this condition.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101790"},"PeriodicalIF":3.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethnic differences in metabolic and histologic features among White, Hispanic, Black and Asian patients with metabolic-associated Steatotic liver disease: A network meta-analysis","authors":"Limin Lin ,&nbsp;Jiaming Lai ,&nbsp;Ling Luo,&nbsp;Junzhao Ye,&nbsp;Bihui Zhong","doi":"10.1016/j.aohep.2025.101780","DOIUrl":"10.1016/j.aohep.2025.101780","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Current evidence on the impact of ethnic disparities on metabolic-associated steatotic liver disease (MASLD) is limited to individual studies with small sample sizes from specific regions. This network meta-analysis aimed to assess variations in metabolism and histological characteristics of MASLD among four ethnicities.</div></div><div><h3>Materials and Methods</h3><div>Observational studies on MASLD involving at least two ethnic groups (White, Black, Asian, and Hispanic) were identified from PubMed, Embase, and Web of Science databases up to May 7th, 2024, for inclusion in this study. The results were reported as unstandardized mean differences (MDs) and odds ratios (ORs) with 95% confidence intervals (CIs).</div></div><div><h3>Results</h3><div>A total of twenty-seven articles involving 14,440 non-Hispanic Whites, 4,927 non-Hispanic Blacks, 5,254 Asians, and 8,344 Hispanic MASLD patients were included in this study. The prevalence of type 2 diabetes mellitus of all ethnic groups combined was 33%, without significant difference among the four ethnicities. Asians showed higher levels of total cholesterol compared to the other groups, while Blacks had the lowest levels of alanine aminotransferase. Among biopsy-proven MASLD patients, Blacks individuals had a lower risk of significant fibrosis compared to Whites (OR=0.63, 95% CI: 0.45 to 0.87), as well as lower risks of liver inflammation (OR=0.53, 95% CI: 0.29 to 0.95) and nonalcoholic steatohepatitis (NASH) (OR=0.53, 95% CI: 0.29 to 0.95) compared to Hispanics.</div></div><div><h3>Conclusions</h3><div>Asians MASLD patients had higher risk of suffering from abnormal lipid metabolism while Black MASLD patients presented milder liver histologic features than both Whites and Hispanics individuals.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101780"},"PeriodicalIF":3.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diastolic dysfunction: Prevalence and outcome in liver transplantation candidates","authors":"Francis Voet ,&nbsp;Maxim Khalenkow ,&nbsp;Michel De Pauw ,&nbsp;Xavier Verhelst ,&nbsp;Sander Lefere ,&nbsp;Anja Geerts ,&nbsp;Hans Van Vlierberghe ,&nbsp;Sarah Raevens","doi":"10.1016/j.aohep.2025.101784","DOIUrl":"10.1016/j.aohep.2025.101784","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Cirrhotic cardiomyopathy (CCM) is a cardiac complication of cirrhosis primarily presenting as diastolic dysfunction (DD). The original diagnostic criteria from 2005 were updated in 2019. This retrospective study aimed to determine the prevalence and clinical impact of DD in liver transplantation (LT) candidates.</div></div><div><h3>Materials and Methods</h3><div>Data from 233 adult cirrhotic LT candidates were analyzed, and echocardiographic data were used to define DD in all patients using the original criteria and the revised criteria.</div></div><div><h3>Results</h3><div>The prevalence of DD was 72,1 % using the original criteria for DD and 6,4 % using the revised criteria. Patients with DD according to the revised criteria were older than those without DD. Other clinical characteristics were similar between groups. Waitlist mortality was 13,3 % in patients with DD versus 9,2 % in patients without DD (NS), according to the revised criteria. A similar percentage of patients with DD (80 %) underwent LT compared to patients without DD (89 %). Post-LT survival rates were comparable between patients with DD (87,3 % by original criteria, 91,7 % by revised criteria) and patients without DD (81,3 % by original and 85,6 % by revised criteria). Notably, lower e’ lateral values pre-LT were associated with post-LT mortality. Major adverse cardiovascular events post-transplantation occurred in 16,7 % of patients with pre-LT DD and in 13,9 % of patients without pre-LT DD (NS).</div></div><div><h3>Conclusions</h3><div>According to the revised criteria, 6,4 % of LT candidates in this cohort had DD. The presence of DD did not significantly impact overall post-transplant mortality.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101784"},"PeriodicalIF":3.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment for hepatocellular carcinoma after immunotherapy","authors":"Landon L. Chan,&nbsp;Tsz Tung Kwong,&nbsp;Johnny C.W. Yau,&nbsp;Stephen L. Chan","doi":"10.1016/j.aohep.2025.101781","DOIUrl":"10.1016/j.aohep.2025.101781","url":null,"abstract":"<div><div>Immunotherapy has revolutionized the treatment landscape for advanced HCC, resulting in prolonged response and improved survival. With these results, a pressing question arises: what is the optimal treatment following first-line immunotherapy? Despite the benefits of immunotherapy, most patients will experience disease progression within six months and will require subsequent therapies. International guidelines recommend second-line multi-kinase inhibitors following progression on immunotherapy; however, this recommendation is primarily based on expert consensus rather than high-quality evidence. Nevertheless, real-world data indicate that these agents demonstrate similar efficacy and safety when used as first-line treatments. Conversely, it remains unclear whether continuing immunotherapy after progression is beneficial. In some cases, adding anti-CTLA-4 as salvage therapy has shown effectiveness. Molecular-directed therapies have also been tested, showing some initial promise, but further data is needed to confirm the benefits of this approach. Emerging evidence suggests that patients experiencing oligoprogression may benefit from local or locoregional therapies while continuing immunotherapy. In this review, we will discuss treatment strategies following progression after first-line immunotherapy.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101781"},"PeriodicalIF":3.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143389936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK)","authors":"Zobair M. Younossi ,&nbsp;James M. Paik ,&nbsp;Linda Henry ,&nbsp;Richard F. Pollock ,&nbsp;Maria Stepanova ,&nbsp;Fatema Nader","doi":"10.1016/j.aohep.2025.101789","DOIUrl":"10.1016/j.aohep.2025.101789","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Non-invasive tests (NITs) identifying high-risk MASLD in primary care is suggested but, these strategies cost-effectiveness remain uncertain in the United Kingdom (UK).</div></div><div><h3>Materials and Methods</h3><div>A cost-utility/budget impact model was developed for cost-effectiveness evaluation of two screening strategies (1) FIB-4 followed by Enhanced Liver Fibrosis (ELF) (FIB-4/ELF); (2) FIB-4 followed by Transient Elastography (FIB-4/TE) compared to standard of care (SoC). A cohort of primary care MASLD patients with an advanced fibrosis prevalence of 4.20 % was simulated. A decision tree classified patients as true positives, false positives, true negatives, or false negatives based on NIT diagnostic accuracy, followed by a 3-year Markov model to estimate costs and quality-adjusted life years (QALYs). The model included 11 health states: MASLD, fibrosis stages (F0–F3), cirrhosis, decompensated cirrhosis, liver transplant, and death. Costs came from the National Tariff, National Schedule of Costs and Personal Social Services Research Unit.</div></div><div><h3>Results</h3><div>SoC had a false diagnosis rate of 36.26 %, while FIB-4 with ELF or TE reduced false positive rates to 23.20 % and 20.91 %, respectively. Compared to 112,807 unnecessary hepatology referrals under SoC, FIB-4/ELF or FIB-4/TE reduced unnecessary referrals by 38,031 (33.71 %) and 45,767 (40.57 %), respectively. Both strategies demonstrated cost-effectiveness relative to SoC with total cost per patient of GBP 983.37 for FIB-4/TE, GBP 993.15 for FIB-4/ELF compared to SoC, GBP 1,014.15.</div></div><div><h3>Conclusions</h3><div>Sequential NIT screening strategies, combining FIB-4 with ELF or TE, are cost-saving, reduce unnecessary hepatology referrals, and offer an efficient (improve outcomes and reduce healthcare costs) approach for managing high-risk MASLD in UK primary care.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101789"},"PeriodicalIF":3.7,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143389926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between red blood cell indices and non-alcoholic fatty liver disease: Prospective study and two-sample Mendelian randomization analysis based on large cohorts","authors":"Rui-ning Li ,&nbsp;Qi-mei Li ,&nbsp;Sheng-xing Liang ,&nbsp;Chang Hong ,&nbsp;Rong-feng Zhang ,&nbsp;Jia-ren Wang ,&nbsp;Hong-bo Zhu ,&nbsp;Hao Cui ,&nbsp;Jing-zhe He ,&nbsp;Yan Li ,&nbsp;Xue-jing Zou ,&nbsp;Wen-yuan Li ,&nbsp;Lin Zeng ,&nbsp;Li Liu ,&nbsp;Lu-shan Xiao","doi":"10.1016/j.aohep.2025.101775","DOIUrl":"10.1016/j.aohep.2025.101775","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Non-alcoholic fatty liver disease (NAFLD) is the primary contributor to persistent chronic liver disease which derives cardiovascular disease, malignancies, and related mortality. There is an association between red blood cell (RBC) indices and the incidence of NAFLD, but the causal relationship has not been determined. We aimed to investigate the association through prospective and Mendelian randomization (MR) analyses.</div></div><div><h3>Materials and Methods</h3><div>The prospective study involved 237,016 participants from the UK Biobank. We employed Cox proportional hazard models and restricted cubic spline models to assess the association between RBC index and NAFLD, and used two-sample MR analysis to identify any causality.</div></div><div><h3>Results</h3><div>Over a mean follow-up of 8.64 years, 2,894 participants from UK Biobank developed NAFLD. The prospective study showed significant associations between high levels of hemoglobin (HGB) (hazard ratio [HR], 1.41; 95 % confidence intervals [CI] 1.24–1.60; <em>P</em> &lt; 0.001), RBC count (HR, 1.20; 95 % CI, 1.07–1.36; <em>P</em> = 0.003) and an increased risk of NAFLD. MR analysis indicated a causal relationship between high HGB levels and NAFLD risk (Odds ratio [OR], 1.55; 95 % CI, 1.11–2.18; <em>P</em> = 0.010). However, there was no observed causal relationship between RBC count and NAFLD.</div></div><div><h3>Conclusions</h3><div>This prospective and MR analysis demonstrated a positive causal relationship between HGB levels and NAFLD. HGB can predict the risk of NAFLD, which can potentially be used as a large-scale non-invasive tool to dynamically monitor the occurrence and development of NAFLD.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101775"},"PeriodicalIF":3.7,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143073229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The promoting effect of the POU3F2/METTL16/PFKM cascade on glycolysis and tumorigenesis of hepatocellular carcinoma","authors":"Ming Chen ,&nbsp;Yuan Yang ,&nbsp;Guangsheng Hu ,&nbsp;Zhong Peng ,&nbsp;Wu Wen","doi":"10.1016/j.aohep.2025.101776","DOIUrl":"10.1016/j.aohep.2025.101776","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><div>Deregulation of m⁶A methylation, the most prevailing RNA modification, participates in cancer pathogenesis. METTL16, an atypical methyltransferase, functions as a pro-tumorigenic factor in hepatocellular carcinoma (HCC). Here, we explored the action of METTL16 on HCC glycolysis and the associated mechanism.</div></div><div><h3>Materials and Methods</h3><div>Expression analysis was done by quantitative PCR, immunoblotting, or immunohistochemistry. Cell sphere formation, invasiveness, apoptosis, proliferation and viability were detected by sphere formation, transwell, flow cytometry, EdU and CCK-8 assays, respectively. Xenograft studies were performed to analyze the role <em>in vivo</em>. Methylated RNA immunoprecipitation (MeRIP) and RIP assays were used to verify the METTL16/PFKM relationship. <em>PFKM</em> mRNA stability was tested by actinomycin D treatment. Chromatin immunoprecipitation (ChIP) and luciferase assays were performed to analyze the POU3F2/<em>METTL16</em> relationship.</div></div><div><h3>Results</h3><div>In HCC, METTL16 expression was elevated, and increased levels of <em>METTL16</em> transcript predicted poor HCC prognosis. METTL16 deficiency resulted in suppressed HCC cell growth, invasiveness and sphere formation. Moreover, METTL16 depletion diminished HCC cell glycolysis. Mechanistically, PFKM expression was positively associated with METTL16 expression. METTL16 mediated m6A methylation to stabilize <em>PFKM</em> mRNA via an IGF2BP3-dependent manner. Restored PFKM expression exerted a counteracting effect on METTL16 deficiency-mediated <em>in vitro</em> cell phenotype alterations and <em>in vivo</em> xenograft growth suppression. Furthermore, POU3F2 promoted the transcription of <em>METTL16</em> in HCC cells.</div></div><div><h3>Conclusions</h3><div>Our findings define the crucial role of the POU3F2/METTL16/PFKM axis in HCC pathogenesis, offering the potential opportunity to combat HCC.</div></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 2","pages":"Article 101776"},"PeriodicalIF":3.7,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor by Rodriguez S et al.","authors":"Carlos Moctezuma-Velazquez","doi":"10.1016/j.aohep.2024.101770","DOIUrl":"10.1016/j.aohep.2024.101770","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101770"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The dual role of HCV protein expression in communication between host cells presents potential applications in the treatment of liver fibrosis","authors":"Junxi Liu,&nbsp;Boda Zhou","doi":"10.1016/j.aohep.2024.101747","DOIUrl":"10.1016/j.aohep.2024.101747","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"30 1","pages":"Article 101747"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}